Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNOSTAR Trial
2024-519798-20-00Phase 2Authorised
- Sponsor
- GOIRC
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of dostarlimab in rectal cancer (2 arms), sponsored by GOIRC. Primary endpoint: Clinical complete response (cCR) and pathological complete response (pCR). Planned start Oct 2025; status: authorised.
02
Drugs
dostarlimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2024-519798-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519798-20-00.